• search
Monoclonal Antibody (mAb) Discovery Services Monoclonal Antibody (mAb) Discovery Services

Monoclonal Antibody (mAb) Discovery Services

We offer wide range of technology platforms, screening tiers, fit-for-purpose tool and therapeutics for monoclonal antibody discovery (mAb).

A robust antibody discovery platform is an important core factor that determines the success of a set of drug modalities. The area of antibody discovery has seen tremendous technological advancement, offering pharma companies a wide range of tools to choose from. At Aurigene, we design our monoclonal antibody discovery services keeping the therapeutic end point in mind and choose the technology platform accordingly. 

Our team has experience in handling several technology platforms including humanized rodents, B-cell cloning, hybridoma, and display libraries. Fit-for-purpose tools and reagent monoclonal antibodies are generated to meet the program needs.

Speak to our experts

Antigen generation and Immunization strategies

  • RNA, membrane and whole cell immunization
  • Immunization with conjugate antigens
  • Immunization with whole-cell, recombinant cell lines, nano disc and membrane preparations
  • Immunization protocols; standard, RImMS and hybrid
  • Neonatal strategy for better epitope specificity and less immunogenic epitope
  • Display technologies: phage, yeast and mammalian: Under development
  • Strong expertise in anti-idiotypic antibody discovery (blockers/non-blockers with single digit nM/pM affinity) to support PK / ADA assays

Hybridoma and B-Cell cloning

  • Antigen-specific single B-cell sorting, sequencing / v-gene recovery, sub-cloning / reformatting, expression, screening and monoclonal selection
  • Enriched B-cell or target-specific B-cell fusion methodologies
  • Highly efficient and optimized fusion (PEG and electrofusion) technologies for generating hybridoma

Screening & evaluation strategies

  • Multitier high-throughput screening strategies using flow cytometry, ELISA, and octet
  • Analytical SE-HPLC, BIAcore, functional assay and mass spectrometry to support analytics
  • Functional assay & fit-for-purpose assay (IHC, Western blotting etc.) for evaluation

Why Aurigene Pharmaceutical Services?

Single B-cell cloning

Humanized rodent platform

Display platforms (Phage/ Yeast)

Hybridoma

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

section

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

rightCaptcha

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen Specific T cells For Cancer Immunotherapy

An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...

Read More

Accelerating Drug Discovery Through Innovative Partnerships

Genomics plays a vital role in identifying which gene is associated with a specific disease. A gene called CNOT1 is for example known for it's effect on brain development and for impairing memory and learning. Despite the great promise genomics provides in understanding the disease, genes are not the best drug targets....

Read More

Expediting early development through innovative precision capsule filling technology

Introduction: Any new chemical entity (NCE) needs to undergo various stages of development such as preclinical and clinical trials before drug product is approved by regulatory agencies and available for patient. Formulations developed during early phases are simple formulations to enable phase appropriate studies like screening, dose ranging, toxicological and d...

Read More

A metal catalyst-free and one-pot synthesis of (3,4- dihydro-2H-benzo[b][1,4]oxazin-2-yl)methanol derivatives in water

2015

A robust and metal catalyst-free method has been developed for the general and green synthesis of racemic (3,4-dihydro-2H-benzo[b][1,4] oxazin-2-yl)methanol derivatives. This simple, mild and practical method involves the reaction of 2-aminophenols with ()-epichlorohydrin in the presence of NaOH in water at room temperature. The reaction features high regioselec...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack